Business Context and Reporting Period
Company: Rentokil Initial plc
Filing Type: Form 6-K (Interim Results)
Reporting Period: Six months ended 30 June 2023
Announcement Date: 27 July 2023
Overview: The Group reported strong operational and financial performance driven by organic growth, effective pricing, and the integration of the Terminix acquisition. The company operates globally across Pest Control, Hygiene & Wellbeing, and France Workwear segments.
Key Financial Metrics (H1 2023)
| Metric | H1 2023 (AER) | H1 2022 (AER) | Change % |
|---|---|---|---|
| Revenue | £2,671m | £1,572m | +69.9% |
| Organic Revenue Growth | 5.9% | 6.2% | - |
| Adjusted EBITDA | £602m | £350m | +72.0% |
| Adjusted Operating Profit | £437m | £233m | +88.0% |
| Adjusted Operating Margin | 16.3% | 14.8% | +150 bps |
| Profit Before Tax (Statutory) | £240m | £162m | +48.1% |
| Diluted Adjusted EPS | 11.41p | 9.45p | +20.7% |
| Free Cash Flow | £229m | £151m | +51.7% |
| Net Debt | £3,270m | £3,296m (FY22) | -£26m |
| Pro Forma Net Debt/Adj EBITDA | 2.8x | 3.2x | -0.4x |
Material Changes vs. Prior Period
- Revenue Surge: Statutory revenue increased 69.9% primarily due to the inclusion of Terminix (North America) and bolt-on M&A. Organic revenue grew 5.9% across all regions, excluding COVID disinfection revenues which fell from £14.2m in H1 2022 to £1.6m in H1 2023.
- Margin Expansion: Group Adjusted Operating Margin improved by 150 basis points to 16.3%. North America margins rose 250 bps to 18.5% due to Terminix synergies. Hygiene & Wellbeing margins decreased 310 bps to 16.5% due to the loss of high-margin COVID disinfection revenue.
- Profitability: Adjusted Operating Profit grew 88.0% to £437m. Statutory Profit Before Tax increased 48.1% to £240m.
- Deleveraging: Net debt decreased slightly to £3.27bn. The pro forma net debt to Adjusted EBITDA ratio improved to 2.8x, ahead of the target to reach 3.0x by year-end.
Guidance, Outlook, and Management Commentary
- Terminix Integration: Management confirmed the integration is on track. H1 2023 delivered $37m in pre-tax net cost synergies, with full-year 2023 guidance of $60m maintained. Total annual synergies are expected to reach at least $200m by FY25.
- M&A Activity: 24 acquisitions were completed in H1 2023 for £202m. The M&A spend guidance for FY23 was raised from c.£250m to c.£300m due to a strong pipeline.
- FX Outlook: Due to the strengthening of GBP against USD, FX guidance for FY23 was revised from a tailwind of £15m-£25m to a headwind of £15m-£20m.
- Margin Guidance: The Group reiterates guidance to grow Group Adjusted Operating Margin to c.16.5% and North America Adjusted Operating Margin to c.19.5% for FY23.
- Dividend: An interim dividend of 2.75p per share was declared, a 14.6% increase year-over-year.
- Risks: Principal risks include integration execution, inflationary pressures, labor market tightness, and termite damage claim provisions (sensitivity analysis indicates a 5% change in claim costs could impact provisions by c.£15m).
Investor Verification Checklist
- Terminix Synergy Realization: Verify the pace of the $60m synergy target delivery in H2 2023, specifically regarding branch consolidation and procurement savings.
- Hygiene & Wellbeing Margin Recovery: Monitor H2 performance to confirm the expected margin rebound (targeted >19.0%) as COVID disinfection headwinds normalize.
- FX Impact: Assess the actual impact of the revised FX headwind (£15m-£20m) on full-year Adjusted PBT.
- Termite Provisions: Review the stability of termite damage claim provisions given the sensitivity to claim rates and costs in the US market.
- M&A Pipeline: Confirm the execution of the raised M&A spend guidance (c.£300m) and the accretive nature of new bolt-on acquisitions.